title: Effect of montelukast on exhaled NO in asthmatic children exposed to relevant allergens.
abstract: The level of exhaled nitric oxide (FENO) is increased in house dust mite (HDM)-sensitized asthmatic children after exposure to HDM antigen, and inhaled steroids can prevent this increase. The aim of this study was to evaluate whether montelukast could prevent an increase in FENO levels in allergic asthmatic children after a brief period of exposure to relevant allergens. Sixteen children were evaluated at the residential house 'Istituto Pio XII' (Misurina, Bellunio, Italy) in the Italian Alps, a dust mite-free environment. FENO levels were evaluated before (t0) and immediately after (t1) the children were exposed to HDM allergens for 2 weeks in their homes at sea level. No significant difference in FENO was observed in the fluticasone-treated group of children after 2 weeks at sea level. In the group treated with montelukast, an increase in FENO was observed between t0 and t1, which failed to reach statistical significance. These preliminary data suggest that oral montelukast could be effective in preventing the relapse in airway inflammation in allergic asthmatic children who are occasionally exposed to relevant allergens for a short period of time.
authors: Clinica Pediatrica, Universita' di Verona, Clinica Pediatrica, II Universita' di Napoli, Istituto Pio XII, Misurina, Belluno, Italy.
authors: Giorgio L
authors: GL
authors: Piacentini
authors: Diego G
authors: DG
authors: Peroni
authors: Michele Miraglia
authors: MM
authors: Del Giudice
authors: Alessandro
authors: A
authors: Bodini
authors: Silvia
authors: S
authors: Costella
authors: Lucia
authors: L
authors: Vicentini
authors: Attilio L
authors: AL
authors: Boner
mesh_terms: D000085:Acetates / Q000627:therapeutic use*; D000293:Adolescent; D000485:Allergens / Q000009:adverse effects; D000730:Androstadienes / Q000627:therapeutic use; D000818:Animals; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy* / Q000276:immunology; D001944:Breath Tests; D002648:Child; D003521:Cyclopropanes; D004391:Dust / Q000009:adverse effects; D000068298:Fluticasone; D006801:Humans; D020024:Leukotriene Antagonists / Q000627:therapeutic use*; D008925:Mites / Q000276:immunology; D009569:Nitric Oxide / Q000032:analysis*; D011804:Quinolines / Q000627:therapeutic use*; D012129:Respiratory Function Tests; D012130:Respiratory Hypersensitivity / Q000188:drug therapy* / Q000209:etiology; D013440:Sulfides; D016896:Treatment Outcome
chemical_list: D000085:Acetates; D000485:Allergens; D000730:Androstadienes; D018927:Anti-Asthmatic Agents; D000893:Anti-Inflammatory Agents; D003521:Cyclopropanes; D004391:Dust; D020024:Leukotriene Antagonists; D011804:Quinolines; D013440:Sulfides; D009569:Nitric Oxide; D000068298:Fluticasone; C093875:montelukast